Spremljaj
Gary Ge
Gary Ge
Druga imenaHuanying ge, Gary Huanying Ge
USC, Amgen, OmicSoft, QIAGEN, VOR Bio
Preverjeni e-poštni naslov na amgen.com
Naslov
Navedeno
Navedeno
Leto
SIRT1 is essential for normal cognitive function and synaptic plasticity
S Michán, Y Li, MMH Chou, E Parrella, H Ge, JM Long, JS Allard, K Lewis, ...
Journal of Neuroscience 30 (29), 9695-9707, 2010
6012010
Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9
M Wei, P Fabrizio, J Hu, H Ge, C Cheng, L Li, VD Longo
PLoS genetics 4 (1), e13, 2008
5852008
FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution
H Ge, K Liu, T Juan, F Fang, M Newman, W Hoeck
Bioinformatics 27 (14), 1922-1928, 2011
3112011
Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension
M Wei, P Fabrizio, F Madia, J Hu, H Ge, LM Li, VD Longo
PLoS genetics 5 (5), e1000467, 2009
2512009
OSA: a fast and accurate alignment tool for RNA-Seq
J Hu, H Ge, M Newman, K Liu
Bioinformatics 28 (14), 1933-1934, 2012
1422012
Inference of transcription modification in long-live yeast strains from their expression profiles
C Cheng, P Fabrizio, H Ge, VD Longo, LM Li
BMC genomics 8, 1-10, 2007
612007
Significant and systematic expression differentiation in long-lived yeast strains
C Cheng, P Fabrizio, H Ge, M Wei, VD Longo, LM Li
PLoS One 2 (10), e1095, 2007
322007
Comparative analyses of time-course gene expression profiles of the long-lived sch9Δ mutant
H Ge, M Wei, P Fabrizio, J Hu, C Cheng, VD Longo, LM Li
Nucleic acids research 38 (1), 143-158, 2010
262010
Haploinsufficiency of the insulin receptor in the presence of a splice-site mutation in Ppp2r2a results in a novel digenic mouse model of type 2 diabetes
M Goldsworthy, Y Bai, CM Li, H Ge, E Lamas, H Hilton, CT Esapa, ...
Diabetes 65 (5), 1434-1446, 2016
252016
Limited differential expression of miRNAs and other small RNAs in LPS-stimulated human monocytes
D Lu, T Yamawaki, H Zhou, WY Chou, M Chhoa, E Lamas, SS Escobar, ...
PloS one 14 (3), e0214296, 2019
142019
RNA-seq analysis pipeline based on oshell environment
J Li, J Hu, M Newman, K Liu, H Ge
IEEE/ACM transactions on computational biology and bioinformatics 11 (5 …, 2014
112014
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
JR Lydeard, MI Lin, HG Ge, A Halfond, S Wang, MB Jones, J Etchin, ...
Molecular Therapy Methods & Clinical Development 31, 2023
92023
A probe-treatment-reference (PTR) model for the analysis of oligonucleotide expression microarrays
H Ge, C Cheng, LM Li
BMC bioinformatics 9, 1-11, 2008
82008
Systems and methods for analyzing microarrays
LM Li, C Cheng, H Ge
US Patent 8,340,915, 2012
52012
P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML …
J Xavier-Ferrucio, C Luo, G Angelini, S Krishnamurthy, N Patel, M Pettiglio, ...
Hemasphere 6, 1312-1313, 2022
22022
G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models
G Canesin, H Hoyt, R Williams, M Silva, M Chng, C Cummins, M Ung, ...
Blood 138, 1716, 2021
22021
Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens
A Halfond, M Ung, J Etchin, Y Keschner, J DiFazio, A Pyclik, ...
Blood 142, 164, 2023
12023
Knock out of CD123 or CLL-1 By CRISPR-Cas9 Editing from Human Hematopoietic Stem Cell Transplants Provide New Possibilities for Increasing Therapeutic Index and Safety for AML …
C Luo, G Angelini, S Krishnamurthy, J Lisle, M Isik, A Ghdossi, ...
Blood 138, 3818, 2021
12021
VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia
J Lydeard, M Lin, C Luo, S Wang, A Halfond, MB Jones, J Scherer, ...
Molecular Therapy, 2021
12021
Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia
D Hazelbaker, M Isik, A Ghodssi, M Ung, A Halfond, S Wang, K Cummins, ...
Molecular Therapy 29 (4), 408-409, 2021
12021
Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.
Članki 1–20